Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand

INTRODUCTION: Liraglutide has demonstrated a significant reduction in the primary major composite cardiovascular (CV) outcome (CV death, non-fatal myocardial infarction, non-fatal stroke). This study aimed to determine the cost–utility of adding liraglutide to the standard of care (SoC) for treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Deerochanawong, Chaicharn, Krittayaphong, Rungroj, Romano, Jack Garcia Uranga, Rhee, Nicolai A., Permsuwan, Unchalee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981833/
https://www.ncbi.nlm.nih.gov/pubmed/36719606
http://dx.doi.org/10.1007/s13300-023-01371-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981833/
https://www.ncbi.nlm.nih.gov/pubmed/36719606
http://dx.doi.org/10.1007/s13300-023-01371-y

Ejemplares similares